1. |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范 (2019年版). 中华消化外科杂志, 2020, 19(1): 1-20.
|
2. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
3. |
Yang N, Han X, Yu J, et al. Hemoglobin, albumin, lymphocyte, and platelet score and neutrophil-to-lymphocyte ratio are novel significant prognostic factors for patients with small-cell lung cancer undergoing chemotherapy. J Cancer Res Ther, 2020, 16(5): 1134-1139.
|
4. |
Jonska-Gmyrek J, Gmyrek L, Zolciak-Siwinska A, et al. Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients. Cancer Manag Res, 2018, 10: 6029-6038.
|
5. |
Yamazaki H, Sugino K, Matsuzu K, et al. Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in anaplastic thyroid carcinoma. Endocrine, 2020, 70(1): 115-122.
|
6. |
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255): 539-545.
|
7. |
Saha S, Biswas SK. Tumor-associated neutrophils show phenotypic and functional divergence in human lung cancer. Cancer Cell, 2016, 30(1): 11-13.
|
8. |
Rawat K, Syeda S, Shrivastava A. Neutrophil-derived granule cargoes: paving the way for tumor growth and progression. Cancer Metastasis Rev, 2021, 40(1): 221-244.
|
9. |
Schmidt H, Bastholt L, Geertsen P, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer, 2005, 93(3): 273-278.
|
10. |
陈媛媛, 蔡晶, 江楚怡. 肿瘤浸润淋巴细胞的过继性T细胞疗法在宫颈癌中的研究进展. 河南医学研究, 2021, 30(1): 189-192.
|
11. |
Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, 1986, 233(4770): 1318-1321.
|
12. |
Paijens ST, Vledder A, de Bruyn M, et al. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol, 2021, 18(4): 842-859.
|
13. |
Sanchez K, Kim I, Chun B, et al. Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer. Breast Cancer Res, 2021, 23(1): 2. doi: 10.1186/s13058-020-01378-4.
|
14. |
Klein S, Mauch C, Brinker K, et al. Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600 E/K mutated malignant melanomas. Sci Rep, 2021, 11(1): 1834. doi: 10.1038/s41598-021-81330-4.
|
15. |
Yao J, Xi W, Chen X, et al. Mast cell density in metastatic renal cell carcinoma: Association with prognosis and tumour-infiltrating lymphocytes. Scand J Immunol, 2021, 93(4): e13006. doi: 10.1111/sji.13006.
|
16. |
Morimoto Y, Nouso K, Wada N, et al. Involvement of platelets in extrahepatic metastasis of hepatocellular carcinoma. Hepatol Res, 2014, 44(14): E353-E359. doi: 10.1111/hepr.12315.
|
17. |
刘双池, 庞青, 谈燚. 血小板在肝细胞癌发生和转移中的研究进展. 中华普通外科学文献 (电子版), 2021, 15(1): 66-69.
|
18. |
夏晓露, 肖玉玲, 邱培, 等. 肝癌根治性切除术后复发的高危因素分析. 实用癌症杂志, 2020, 35(11): 1875-1878.
|
19. |
Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer, 2018, 6(1): 74. doi: 10.1186/s40425-018-0383-1.
|
20. |
Ji F, Liang Y, Fu SJ, et al. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI). BMC Cancer, 2016, 16: 137. doi: 10.1186/s12885-016-2189-1.
|
21. |
Wang D, Bai N, Hu X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ, 2019, 7: e7132. doi: 10.7717/peerj.7132.
|
22. |
Zheng J, Cai J, Li H, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem, 2017, 44(3): 967-981.
|
23. |
Chen Y, Zeng J, Guo P, et al. Prognostic significance of platelet-to-lymphocyte ratio (PLR) in extrahepatic metastasis of hepatocellular carcinoma after curative resection. Cancer Manag Res, 2021, 13: 1395-1405.
|
24. |
Kwon HM, Moon YJ, Jung KW, et al. Neutrophil-to-lymphocyte ratio is a predictor of early graft dysfunction following living donor liver transplantation. Liver Int, 2019, 39(8): 1545-1556.
|
25. |
Harimoto N, Yoshizumi T, Shimagaki T, et al. Inflammation-based prognostic score in patients with living donor liver transplantation for hepatocellular carcinoma. Anticancer Res, 2016, 36(10): 5537-5542.
|
26. |
Lai Q, Melandro F, Larghi Laureiro Z, et al. Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: a systematic review and meta-analysis. World J Gastroenterol, 2018, 24(15): 1658-1665.
|
27. |
Ismael MN, Forde J, Milla E, et al. Utility of inflammatory markers in predicting hepatocellular carcinoma survival after liver transplantation. Biomed Res Int, 2019, 2019: 7284040. doi: 10.1155/2019/7284040.
|
28. |
Ren A, Li Z, Zhang X, et al. Inflammation-based prognostic scores in patients with hepatitis B virus-related hepatocellular carcinoma after liver transplantation. J Hepatocell Carcinoma, 2020, 7: 101-106.
|
29. |
Fan W, Zhang Y, Wang Y, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One, 2015, 10(3): e0119312. doi: 10.1371/journal.pone.0119312.
|
30. |
Li S, Feng X, Cao G, et al. Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: a systematic review and meta-analysis. PLoS One, 2020, 15(3): e0230879. doi: 10.1371/journal.pone.0230879.
|
31. |
He C, Zhang Y, Cai Z, et al. The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. Cancer Manag Res, 2019, 11: 1391-1400.
|
32. |
Guo L, Ren H, Pu L, et al. The prognostic value of inflammation factors in hepatocellular carcinoma patients with hepatic artery interventional treatments: a retrospective study. Cancer Manag Res, 2020, 12: 7173-7188.
|
33. |
Chu MO, Shen CH, Chang TS, et al. Pretreatment inflammation-based markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation. Sci Rep, 2018, 8(1): 16611. doi: 10.1038/s41598-018-34543-z.
|
34. |
Chen K, Zhan MX, Hu BS, et al. Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma. Oncol Lett, 2018, 15(1): 315-323.
|
35. |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4): 378-390.
|
36. |
Liu L, Gong Y, Zhang Q, et al. Prognostic roles of blood inflammatory markers in hepatocellular carcinoma patients taking sorafenib. A systematic review and meta-analysis. Front Oncol, 2020, 9: 1557. doi: 10.3389/fonc.2019.01557.
|
37. |
Hong YM, Yoon KT, Hwang TH, et al. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol, 2019, 31(10): 1250-1255.
|
38. |
Casadei-Gardini A, Dadduzio V, Rovesti G, et al. Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. Medicine (Baltimore), 2020, 99(22): e19958. doi: 10.1097/MD.0000000000019958.
|